Latest News
Three scientists – renowned for scientific breakthroughs in Alzheimer’s, macular degeneration and glaucoma and who were given key early support from BrightFocus – have been elected as members of the prestigious National Academy of Medicine.
BrightFocus Foundation, a premier source of private research funding to defeat Alzheimer’s disease, macular degeneration, and glaucoma, today announced the addition of Sharyn Rossi, PhD, to its senior staff as the organization’s new Director of Scientific Programs, Neuroscience.
The WHAM! (Women’s Health Access Matters!) Investigators Fund today announced $100,000 in support from BrightFocus Foundation for sex and gender-specific research to advance women’s brain health.
Learn about a new FDA-approved long-term glaucoma treatment, the benefits and risks of glaucoma surgery, research exploring how pressure in the eye is regulated, risk factors for the development of glaucoma, and more in the fall edition of Natonal Glaucoma Research Report.
In animal experiments, scientists document that the APOE4 allele impacts cell bioenergetics in the entorhinal cortex, a critical brain region first damaged in Alzheimer’s disease (AD).
Scientists describe how the protein tau is modified over four decades as Alzheimer’s develops and progresses.
New partnerships with BrightFocus Foundation and CURE will promote research, clinical trials in neurology practices nationwide
BrightFocus Foundation mourns the recent passing of Peter Davies, PhD. A globally-recognized leader in research on Alzheimer’s and related dementia, Dr. Davies served on our Scientific Review Committee for this field for 11 years, including six years as its chair.